Recent developments highlight RetinalGenix’s progress in advancing its genetic testing and retinal imaging platforms, strategic collaborations, and management appointments, alongside ongoing efforts to support clinical studies and expand its advisory team.

• RetinalGenix reported on its science and mission in light of a new AI-driven retinal mapping study, emphasizing its integrated approach to early disease detection [N1].
• The company agreed to hire M. Cory Zwerling as CFO and Interim COO to strengthen its management team [N2].
• RetinalGenix contracted with Seer Bio to explore early detection of neurodegenerative, systemic, and retinal diseases [N3].
• A strategic collaboration was announced with RGEN Clinical Genotyping Laboratory to advance early detection of neurodegenerative, systemic, and retinal diseases [N4].
• The company contracted with LabCorp to support its DNA/GPS platform for advanced genetic and retinal health screening [N5].
• Dr. Taimour Langaee was welcomed as an advisor for DNA GPS pharmacogenetics initiatives [N6].
• RetinalGenix announced a laboratory lease agreement with life science incubator MBC BioLabs to support its research activities [N7].
• The company contracted with MEDsan, Inc. to provide diagnostic testing services for an Institutional Review Board study personalizing medical evaluations for wet macular degeneration patients [N8].

RetinalGenix’s integrated platform combining genetic testing, retinal imaging, and AI-driven data analytics could enable early detection and personalized treatment of eye and systemic diseases, addressing significant unmet medical needs. The planned launch of genetic tests and the RetinalCam™ device may open new market opportunities in home and remote ocular monitoring. Strategic collaborations and a growing advisory team support clinical development and potential pharmaceutical product advancement. The company’s focus on cost-effective, patient-controlled health information systems may facilitate broader healthcare access and improved patient outcomes.

RetinalGenix has no approved products or revenue and faces substantial liquidity challenges, with a current ratio of 0.01 and significant accumulated deficits. The company’s ability to continue operations depends on raising additional capital, which is uncertain. Product development and commercialization timelines are lengthy and subject to regulatory and market acceptance risks. Material weaknesses in internal controls and limited operating history add to operational risks. Competition from larger, established companies with greater resources may limit market penetration. Failure to achieve profitability or secure funding could force reduction or cessation of operations.

RetinalGenix’s moat is based on its integrated approach combining genetic testing, retinal imaging, patient-controlled data systems, and pharmaceutical therapies targeting ocular and systemic diseases. The company leverages proprietary pharmacogenetic mapping and high-resolution retinal imaging technologies, supported by a secure anonymized AI database designed to facilitate early disease detection and personalized treatment. Strategic collaborations with third-party laboratories and clinical organizations, along with a growing patent portfolio and specialized expertise, contribute to its competitive positioning. However, the company faces competition from larger, better-funded entities and must overcome significant development, regulatory, and commercialization challenges to establish a sustainable market presence.

• Liquidity and Going Concern Risk: The company has limited cash and a current ratio of 0.01 as of December 31, 2025, with substantial doubt about its ability to continue as a going concern without additional funding [S1][S2].
• Product Development and Commercialization Risk: RetinalGenix has no approved products and has not generated revenue. Product development timelines are uncertain, and there is no assurance of successful commercialization or regulatory clearance [S1].
• Financial Reporting and Internal Controls Risk: Management has identified material weaknesses in internal controls over financial reporting due to lack of segregation of duties, with remediation constrained by funding [S2].
• Competitive Risk: The company faces competition from larger, better-funded companies with established distribution networks and expertise in research, development, and regulatory approvals [S1].
• Funding and Capital Raising Risk: RetinalGenix’s operations depend on its ability to raise additional capital through equity, debt, or partnerships. Failure to secure funding could adversely impact operations and growth plans [S1][S2].
• Market Acceptance and Reimbursement Risk: The commercial success of future products depends on market acceptance, pricing, and reimbursement, which are uncertain and may affect profitability [S1].
• Operational and Management Risk: The company relies heavily on key personnel and has a limited operating history, which may affect its ability to execute its business plan effectively [S1].

• RetinalGenix Technologies Inc. is an ophthalmic research and development company focused on technologies to screen, provide information, and treat eye health disorders, including sight-threatening diseases [S1].
• The company’s mission is to improve patient outcomes by providing critical information to patients and physicians for eye and general health conditions [S1].
• RetinalGenix’s business model is built on four pillars: genetic testing, retinal imaging, patient informational database, and pharmaceutical therapies [S1].
• Genetic testing products, including GPS oral swab tests, are planned for launch in late 2026, with a second genetic test targeting wet AMD responders planned for 2027 [S1].
• The Retinal Imaging Platform includes the RetinalCam™, a portable retinal imaging device for home and remote monitoring, designed to operate without pupil dilation and provide real-time physician alerts 24/7; beta testing is planned for 2026 with potential commercialization in 2027 [S1].
• The Patient Informational Database (RECAD™ AI system) is being developed as a secure, interoperable system controlled by patients to combine genetic and imaging data anonymously for use with physicians [S1].
• Pharmaceutical therapies under development include RTG-2023 for dry age-related macular degeneration and RTG-2024 for Alzheimer’s syndrome dementia, with clinical studies planned subject to funding [S1].
• The company has no products approved for sale and has not generated revenue from product sales to date [S1].
• RetinalGenix has engaged in multiple collaborations and contracts, including with Seer Bio, RGEN Clinical Genotyping Laboratory, LabCorp, and MEDsan, Inc., to support early detection research and diagnostic testing services [N3][N4][N5][N8].
• The company has appointed advisors and expanded its team to support DNA/GPS pharmacogenetics initiatives and clinical development [N6].
• RetinalGenix has leased laboratory space at MBC BioLabs, a life science incubator, to support its operations [N7].
• The company has experienced net losses and an accumulated deficit since inception, with a net loss of approximately $2.43 million and EPS of -$0.13 for the year ended December 31, 2025 [S1][S2].
• As of December 31, 2025, RetinalGenix had cash and equivalents of $14,774 and current liabilities of approximately $2.32 million, resulting in a current ratio of 0.01, indicating liquidity challenges [S1].
• The company has substantial doubt about its ability to continue as a going concern without additional funding [S1][S2].
• RetinalGenix has raised capital primarily through private placements of common stock, including approximately $1.2 million raised during 2024 and 2025 [S1].
• The company’s management has identified material weaknesses in internal controls over financial reporting due to lack of segregation of duties, with remediation efforts limited by funding constraints [S2].
• RetinalGenix faces risks related to its limited operating history, lack of revenue, need for substantial additional funding, and uncertainties in product development and commercialization [S1][S2].
• The company’s products do not currently require FDA approval for the RetinalCam™ device, which is intended for screening and monitoring [S1].
• RetinalGenix’s strategy includes leveraging AI and anonymized patient data to improve early detection and treatment of ocular and systemic diseases [S1].
• The company’s ownership is concentrated, with directors, officers, and principal stockholders owning approximately 79% of outstanding shares as of April 15, 2026 [S1].